Gilead Sciences Inc
GILD: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$31.00 | Kdvyw | Tkgcybwf |
Gilead: Maintaining Our $97 Fair Value Estimate as CymaBay Acquisition Looks Like a Good Fit
Gilead is acquiring CymaBay and its oral PPAR-delta agonist seladelpar for $4.3 billion in an effort to expand its liver disease portfolio. We think this is a good complement to Gilead’s existing hepatitis C portfolio of drugs, and we’re not making any changes to our $97 Gilead fair value estimate. Overall, we think HIV and oncology sales remain the biggest supports for Gilead’s wide moat.